Incidence and Impact of ICU-acquired Diaphragm Weakness

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAssistance Publique - Hôpitaux de Paris

About this trial

ICU survivors are at an increased risk of hospital and ICU readmission. Among the complications of ICU stay, diaphragmatic dysfunction is common, with a prevalence of 60 to 80%, and is associated with increased mortality and prolonged hospital stays. Furthermore, several studies have reported that the observation of impaired respiratory muscle function upon ICU discharge is associated with a poor long-term prognosis. However, the incidence and prognostic impact of persistent diaphragmatic dysfunction at ICU discharge have never been evaluated. The measurement of dyspnea, a composite evaluation of respiratory muscle function, has not been assessed for predicting prognosis upon ICU discharge.

The hypothesis of the project is that the presence of ICU-acquired diaphragmatic dysfunction at ICU discharge is associated with a poorer prognosis within 90 days.

Eligibility criteria

Qualifiers

Age ≥ 18 years

Invasive or non-invasive respiratory support (ventilation, high-flow oxygen therapy, whatever the reason) for at least 48 hours.

Weaning from respiratory support (invasive or not) within the last 24 hours.

Patient (or trusted person/relative) informed and not opposed to the study.

Disqualifiers

Known pre-existing diaphragmatic dysfunction (phrenic lesion, neuromuscular disease, etc.)

Patients with tracheostomy

Non-communicating patients

Patients deprived of liberty by court or administrative order, or under legal protection (guardianship, curators).

Trial design

Treatments tested in this trial

  • Diaphragmatic ultrasound and data collection

Treatment groups

194 Participants
are divided into 1 treatment group